Fubotv earnings beat by $0.10, revenue topped estimates
In a recent 8-K filing with the U.S. Securities and Exchange Commission, GE HealthCare (NASDAQ:GEHC) Technologies Inc. (market cap: $32.8 billion) announced the outcomes of its annual stockholder meeting held on May 28, 2025. According to InvestingPro data, the company maintains a "GOOD" overall financial health score and trades at an attractive P/E ratio of 14.1x. The meeting resulted in the re-election of 10 directors, approval of executive compensation, ratification of the company’s independent auditor, and rejection of a stockholder proposal concerning termination pay arrangements. As a prominent player in the Healthcare Equipment & Supplies industry generating $19.8 billion in revenue over the last twelve months, these governance decisions carry significant weight.
The elected directors will serve a one-year term until the 2026 annual meeting or until their successors are elected and qualified. The advisory vote on named executive officers’ compensation was approved, indicating stockholder support for the company’s executive pay practices.
Furthermore, stockholders ratified the appointment of Deloitte & Touche LLP as the independent auditor for the fiscal year ending December 31, 2025. However, a stockholder proposal regarding the ratification of certain termination pay arrangements did not pass.
The detailed voting results for each nominee and proposal were provided in the filing, including the number of votes for and against, abstentions, and broker non-votes. The filing, signed by General Counsel and Corporate Secretary Frank R. Jimenez, confirms the official decisions made during the meeting.
This 8-K filing reflects the latest corporate governance actions taken by GE HealthCare Technologies Inc., a company incorporated in Delaware and headquartered in Chicago, IL. The filing is based on a press release statement from the company.
In other recent news, GE HealthCare Technologies Inc. reported strong financial results for the first quarter of 2025, with revenue reaching $4.8 billion, reflecting a 4% organic growth. The company also saw a 12% year-over-year increase in adjusted earnings per share (EPS), which rose to $1.01. GE HealthCare achieved a record backlog of $20.6 billion, indicating robust demand for its products and services. The company launched several innovative products, including a new PET imaging agent, which contributed to its growth. Analysts have noted that GE HealthCare’s strategic initiatives and innovative product launches are positioning it well in the competitive market. Despite potential challenges from tariffs and a projected decline in the Chinese market, the company remains confident in its ability to mitigate these impacts. For the full year 2025, GE HealthCare projects organic revenue growth between 2% and 3% and expects adjusted EPS in the range of $3.90 to $4.10.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.